Literature DB >> 32374880

BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation.

Eduardo Espada1,2, Matthew P Cheng1,3, Haesook T Kim4, Ann E Woolley1,3, Jason I Avigan1, Edouard Forcade5, Maria V D Soares2, João F Lacerda2, Sarah Nikiforow1, Mahasweta Gooptu1, Rizwan Romee1, Edwin P Alyea1, Philippe Armand1, Corey S Cutler1, Vincent T Ho1, John Koreth1, Joseph H Antin1, Robert J Soiffer1, Francisco M Marty1,3, Jerome Ritz1.   

Abstract

Clinical disease caused by BK virus reactivation is a frequent complication of allogeneic hematopoietic cell transplantation (HCT). Because of the lack of effective antiviral agents, BK virus-specific T cells are emerging as a potential therapy for BK virus disease, but the immune response to BK virus after allogeneic HCT has not been well characterized. Our study describes reconstitution of BK virus-specific T-cell immunity in 77 adult patients after HCT. All patients had urinary symptoms, and urine was tested for BK virus replication; 33 patients were positive for BK virus (cases), and 44 were negative (controls). In BK virus cases, the median time to first positive test was 75 days (range, 2-511). BK virus cases had lower CD4 T-cell counts 3 to 9 months after transplant, but CD8 T-cell counts were similar in cases and controls. BK virus-specific T cells were identified by cytokine flow cytometry in cryopreserved samples collected prospectively. BK virus-specific CD4 T cells producing T helper 1 (Th1) cytokines recovered quickly after HCT. BK virus-specific T cells were detected more frequently in patients with BK virus reactivation at most time points, and CD4 T cells producing Th1 cytokines were more frequent than BK virus-specific cytolytic CD8 T cells. Early detection of interferon-γ+ and cytolytic BK virus-specific CD4 T cells was associated with lower rates of hematuria among cases. Overall, our study describes recovery of BK virus-specific T cells after HCT and the distinct roles for BK virus-specific T cells in the development and resolution of clinical symptoms.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2020        PMID: 32374880      PMCID: PMC7218418          DOI: 10.1182/bloodadvances.2019001120

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  25 in total

1.  Antibodies to BK virus in children prior to allogeneic hematopoietic cell transplant.

Authors:  Benjamin L Laskin; Kathleen E Sullivan; Jeff Hester; Jens Goebel; Stella M Davies; Sonata Jodele
Journal:  Pediatr Blood Cancer       Date:  2015-04-01       Impact factor: 3.167

2.  Intracellular cytokine optimization and standard operating procedure.

Authors:  Laurie Lamoreaux; Mario Roederer; Richard Koup
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

Review 3.  IL-2 and polyoma BK virus infection; A systematic review article.

Authors:  Ashraf Kariminik
Journal:  Cytokine       Date:  2016-10-05       Impact factor: 3.861

4.  Presentation of BK polyomavirus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation.

Authors:  Hannah Imlay; Hu Xie; Wendy M Leisenring; Elizabeth R Duke; Louise E Kimball; Meei-Li Huang; Steven A Pergam; Joshua A Hill; Keith R Jerome; Filippo Milano; W Garrett Nichols; Phillip S Pang; Hans H Hirsch; Ajit P Limaye; Michael Boeckh
Journal:  Blood Adv       Date:  2020-02-25

5.  Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40.

Authors:  Wendy A Knowles; Pam Pipkin; Nick Andrews; Andrew Vyse; Philip Minor; David W G Brown; Elizabeth Miller
Journal:  J Med Virol       Date:  2003-09       Impact factor: 2.327

6.  BK polyomavirus-specific cellular immune responses are age-dependent and strongly correlate with phases of virus replication.

Authors:  T Schmidt; C Adam; H H Hirsch; M W W Janssen; M Wolf; J Dirks; P Kardas; T Ahlenstiel-Grunow; L Pape; T Rohrer; D Fliser; M Sester; U Sester
Journal:  Am J Transplant       Date:  2014-04-11       Impact factor: 8.086

7.  Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.

Authors:  Ifigeneia Tzannou; Anastasia Papadopoulou; Swati Naik; Kathryn Leung; Caridad A Martinez; Carlos A Ramos; George Carrum; Ghadir Sasa; Premal Lulla; Ayumi Watanabe; Manik Kuvalekar; Adrian P Gee; Meng-Fen Wu; Hao Liu; Bambi J Grilley; Robert A Krance; Stephen Gottschalk; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Ann M Leen; Bilal Omer
Journal:  J Clin Oncol       Date:  2017-08-07       Impact factor: 44.544

8.  Standardization of cytokine flow cytometry assays.

Authors:  Holden T Maecker; Aline Rinfret; Patricia D'Souza; Janice Darden; Eva Roig; Claire Landry; Peter Hayes; Josephine Birungi; Omu Anzala; Miguel Garcia; Alexandre Harari; Ian Frank; Ruth Baydo; Megan Baker; Jennifer Holbrook; Janet Ottinger; Laurie Lamoreaux; C Lorrie Epling; Elizabeth Sinclair; Maria A Suni; Kara Punt; Sandra Calarota; Sophia El-Bahi; Gailet Alter; Hazel Maila; Ellen Kuta; Josephine Cox; Clive Gray; Marcus Altfeld; Nolwenn Nougarede; Jean Boyer; Lynda Tussey; Timothy Tobery; Barry Bredt; Mario Roederer; Richard Koup; Vernon C Maino; Kent Weinhold; Giuseppe Pantaleo; Jill Gilmour; Helen Horton; Rafick P Sekaly
Journal:  BMC Immunol       Date:  2005-06-24       Impact factor: 3.615

9.  A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation.

Authors:  Francisco M Marty; Drew J Winston; Roy F Chemaly; Kathleen M Mullane; Tsiporah B Shore; Genovefa A Papanicolaou; Greg Chittick; Thomas M Brundage; Chad Wilson; Marion E Morrison; Scott A Foster; W Garrett Nichols; Michael J Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2018-10-04       Impact factor: 5.742

10.  Seroepidemiology of human polyomaviruses.

Authors:  Jaime M Kean; Suchitra Rao; Michael Wang; Robert L Garcea
Journal:  PLoS Pathog       Date:  2009-03-27       Impact factor: 6.823

View more
  4 in total

1.  Incidence, risk factors and outcome of BK virus hemorrhagic cystitis following allogenic hematopoietic cell transplantation: a retrospective cohort study.

Authors:  Gérard Socié; Jean-Michel Molina; Anastasia Saade; Julien Gras; Michael Darmon; David Michonneau; Nathalie Dhedin; Linda Feghoul; Jérôme Le Goff; Aliénor Xhaard; Régis Peffault De Latour
Journal:  Bone Marrow Transplant       Date:  2022-05-20       Impact factor: 5.174

2.  In Vitro Generation of BK polyomavirus-specific T cells for adoptive cell therapy in refractory cystitis hemorrhagic patients after hematopoietic stem cell transplantation.

Authors:  Maryam Mohammadi Najafabadi; Masoud Soleimani; Mohammad Ahmadvand; Mina Soufi Zomorrod; Seied Asadollah Mousavi
Journal:  BMC Immunol       Date:  2022-06-10       Impact factor: 3.594

Review 3.  Viral Infections in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications.

Authors:  Claudio Annaloro; Fabio Serpenti; Giorgia Saporiti; Giulia Galassi; Francesca Cavallaro; Federica Grifoni; Maria Goldaniga; Luca Baldini; Francesco Onida
Journal:  Front Immunol       Date:  2021-01-20       Impact factor: 7.561

4.  Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy.

Authors:  Agnes Bonifacius; Sabine Tischer-Zimmermann; Maria Michela Santamorena; Philip Mausberg; Josephine Schenk; Stephanie Koch; Johanna Barnstorf-Brandes; Nina Gödecke; Jörg Martens; Lilia Goudeva; Murielle Verboom; Jana Wittig; Britta Maecker-Kolhoff; Herrad Baurmann; Caren Clark; Olaf Brauns; Martina Simon; Peter Lang; Oliver A Cornely; Michael Hallek; Rainer Blasczyk; Dominic Seiferling; Philipp Köhler; Britta Eiz-Vesper
Journal:  Front Bioeng Biotechnol       Date:  2022-04-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.